Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054979 | 0.91 | PTGIR (0.69) | PTGIRADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL4032956 | 0.84 | PTGIR (0.62) | PTGIRADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL4035161 | 0.83 | PTGIR (0.61) | PTGIRADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL17186490 | 0.83 | PTGIR (0.61) | PTGIRADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL10800812 | 0.83 | PTGIR (0.83) | PTGIRADRA2AADRA2BADRA2CCXCR4 | |
| SCHEMBL11132646 | 0.83 | CXCR4 (0.56) | PTGIRADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL26703926 | 0.83 | PTGIR (0.61) | PTGIRADRA2AADRA2BADRA2CLMNA | |
| Hydrochloric Acid SCHEMBL18605409 | 0.81 | PTGIR (0.59) | PTGIRADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL6300545 | 0.81 | WDR5 (0.53) | PTGIRADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL13063330 | 0.81 | CYP2D6 (0.58) | PTGIRADRA2AADRA2BADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652055-B2 | 2-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | claimed |
| US-20090018180-A1 | 2-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | US | claimed |
| CN-114929690-A | Novel heterocyclic derivatives with cardiomyocyte proliferative activity for the treatment of cardiac diseases | 同济大学 | 2022-08-19 | — | — | CN | disclosed |
| US-7741493-B2 | 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease | AVENTIS PHARMACEUTICALS INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1651613-B1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMA INC (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-2173720-A2 | 2-IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) | F. Hoffmann-Roche AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| CN-101687812-A | The 2-imidazolinium compounds that trace amine associated receptors (TAAR) is had good affinity | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | disclosed |
| US-7652055-B2 | 2-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652055-B2 | 2-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652055-B2 | 2-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090018180-A1 | 2-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | US | disclosed |
| WO-2009003868-A2 | 2 -IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003868-A2 | 2 -IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7326792-B2 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1651613-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | Aventis Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014555-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
| US-3983133-A | CNS ANTIDEPRESSANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-09-28 | — | — | US | disclosed |
| US-3963718-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS | JANSSEN PHARMACEUTICA (BE) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018180-A1 | 2-IMIDAZOLINES | TAAR1, TAAR5, NPY1R | PTGIR 286/4885ADRA2A 61/4885ADRA2B 108/4885 |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | P2RX3, P2RX2, P2RX5 | PTGIR 571/4885ADRA2A 430/4885ADRA2B 316/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | PTGIR 571/4885ADRA2A 430/4885ADRA2B 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.